Posted by Michael Wonder on 11 Jun 2026
Zemcelpro (UM171 cell therapy) licensing and supply agreements announced for Canada
10 June 2026 - ExCellThera today announced exclusive licensing and supply agreements granting Medexus the Canadian commercialization rights for Zemcelpro (dorocubicel), also known as UM171 cell therapy.
Zemcelpro is a novel personalized cryopreserved hematopoietic stem cell transplantation product containing two components, namely UM171 expanded CD34 positive cells (dorocubicel) and unexpanded CD34 negative cells, each derived from the same cord blood unit.
